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Outcomes of internal hemipelvectomy for pelvic
tumors: a developing country’s prospective
Masood Umer, FCPS, Moiz Ali, MBBS*, Rizwan H. Rashid, FCPS, Yasir Mohib, FCPS, Haroon U. Rashid, FCPS
Introduction: Previously, external hemipelvectomy was the mainstay of treatment for pelvic tumors. However, with technological
advancements, limb salvage procedures such as internal hemipelvectomy have emerged as a viable alternative. However, there is
limited literature available on long-term outcomes and complications of internal hemipelvectomy, especially from developing
countries. Therefore, the objective of this study was to share our experience of internal hemipelvectomy at a tertiary care center in a
developing country.
Materials and methods: A retrospective review was conducted in which all 24 patients undergoing internal hemipelvectomy from
January 1, 2005 to December 31, 2015 at our institution were included. Medical record ﬁles were reviewed for intraoperative and
early and late postoperative complications, and functional outcomes were assessed by contacting each patient on telephone.
Results: Ewing sarcoma was found to be the most common diagnosis, followed by osteosarcoma as the second most common.
The mean follow-up period was 18.7±13.9 months. Intraoperatively there were 4 cases of iatrogenic neurovascular injury and 2
cases each of urinary tract injury and dural tear. Four patients developed early wound infections, 7 developed late wound infections,
and 2 developed ﬂap necrosis. Three patients developed recurrence, whereas 7 patients developed metastasis postoperatively. The
mean survival was calculated to be 28 months and the mean Musculoskeletal Tumor Society score was 19.3±5.2.
Conclusions: Outcomes and prevalence of complications shown in this study are comparable to those in the international
literature, which suggests that hemipelvectomy is a viable option in developing countries also. However, more such studies are
warranted to validate the ﬁndings and to identify the challenges and morbidities associated with hemipelvectomy in Asian and
developing countries.
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Primary bone sarcomas of the pelvis account for only 5%–10%
of all malignant bone tumors, but individual importance is still
given to this region because of its anatomic complexity [1–4].
These tumors also tend to present late and therefore pose a major
challenge for orthopedic oncologists because of the large tumor
size, local extension, and complex anatomy with proximity to
major neurovascular structures and intestinal and urinary tracts.
Subsequently, these are also associated with less favorable out-
comes in terms of prognosis and survival compared with other
extremity tumors [2,5–7].
Previously, the mainstay for treatment of malignant pelvic
tumors was external hemipelvectomy (hindquarter amputation),
but with advancements in surgical techniques and chemotherapy
and radiation therapy, limb salvage procedures (internal
hemipelvectomy) have also emerged as viable modalities [5]. This
involves resection of the lesion with part or all of the hemipelvis,
but preserving the ipsilateral lower extremity. In patients in
whom the tumor has not invadedmajor neurovascular structures,
wide resection is possible, and therefore internal hemipelvectomy
can be considered without affecting the functionality of the limb.
However, in cases of neurovascular invasion and where wide-
margin excision is difﬁcult, external hemipelvectomy remains the
preferred option [8,9].
Whether internal or external, hemipelvectomy is a major sur-
gical procedure and may be associated with signiﬁcant morbidity
and functional impairments including injury to gastrointestinal
or genitourinary tract, neurovascular injury, considerable soft
tissue defects, blood loss, wound infections, and delayed wound
healing [5,9,10]. As hemipelvectomy requires special expertise and
is not a commonly performed procedure, there is scarcity of lit-
erature available on its long-term complications and outcomes,
especially from developing countries where there is a lack of
resources and training. Therefore, the aim of this study was to
share our 10 years’ experience of internal hemipelvectomy at a
tertiary care center from a developing country’s prospective.
Materials and methods
A retrospective review was conducted between January 1, 2005
and December 31, 2015 in which all patients undergoing internal
hemipelvectomy for pelvic tumors were included. All surgeries
were performed by a single fellowship-trained orthopedic
oncologist at our hospital. The study was approved by the Ethics
Review Committee at our institution.
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Medical record ﬁles for all 24 patients included in the study
were reviewed. All patients had undergone blood and radiologic
work up before surgery. Radiologic investigations included x-ray
pelvis and chest and magnetic resonance imaging of pelvis to
identify the extent of disease, and only those patients were offered
internal hemipelvectomy in whom complete excision of tumor
seemed possible. The ﬁnal tumor size was noted from the ﬁnal
histopathologic report of the specimen and was categorized on
the basis of the largest diameter being either ≥20 cm, between 10
and 20 cm, or < 10 cm[9]. All musculoskeletal tumors were staged
according to the Enneking system of staging for malignant and
benign musculoskeletal tumors. Metastatic pelvic carcinomas
from other primary sources were classiﬁed as stage IV. Internal
hemipelvectomy was further classiﬁed according to the Enneking
and Dunham classiﬁcation, and an en bloc resection of the ilium
and sacral ala was classiﬁed as type IV[11,12]. Administration of
neoadjuvant and/or adjuvant chemoradiation therapy was
dependent on the diagnosis, and the number of cycles given was
noted. The percentage response to neoadjuvant therapy in terms
of tumor necrosis was also noted from the ﬁnal histopathology
report.
Intraoperative, early postoperative (during the hospital stay),
and late postoperative (on follow-up visits) complications were
noted and their management was also reviewed. Functional
outcome after the surgery was assessed using theMusculoskeletal
Tumor Society (MSTS) scoring system. Patients were contacted
and interviewed on telephone to calculate the MSTS score. For
patients who were deceased before the study, their cause and time
duration after the primary surgery for the mortality were
obtained from the family. Subsequently, the average survival rate
was calculated using Kaplan-Meier analysis. Independent sample
t test was used for comparison of means, whereas χ2 test was used
for categorical variables. A P-value of < 0.05 was considered
signiﬁcant.
Results
Table 1 describes the characteristics for all included patients. Of a
total of 24 patients, 14 (58.3%) were male and 10 (41.7%)
female, and their mean age was 23.6 ± 13.6 years. The most
common diagnosis for primary pelvic tumor was found to be
Ewing sarcoma (50%), whereas second most common diagnosis
was osteosarcoma (12.5%). Three patients (12.5%) underwent
internal hemipelvectomy for metastases of lung, rectal, and
endometrial carcinomas with the intention of palliative treatment
and pain relief. A total of 8 patients (33.3%) required recon-
struction and ﬂap coverage, and the most common type of ﬂap
used was the rectus abdominus ﬂap (75%), whereas the vastus
lateralis ﬂap and the anterolateral thigh ﬂap were used in 1
patient each. The mean duration of surgery was calculated to be
356 ± 108 minutes, the mean length of hospital stay was
11.3 ± 6.5 days, whereas the mean follow-up period was
18.7 ± 13.9 months. There were 5 patients who were lost to fol-
low-up.
All but 1 patient suffering from Ewing sarcoma received
neoadjuvant chemotherapy with a mean of 7 cycles (range, 4–18
cycles). Of these 11 patients, 2 were also given neoadjuvant
radiotherapy. Six patients also required adjuvant chemotherapy
with a mean of 5.7 cycles, whereas one of them received con-
comitant adjuvant radiotherapy also. All 3 patients with
osteosarcoma received neoadjuvant chemotherapy with a mean
of 4.3 cycles and none of them required any adjuvant treatment.
All patients with other primary carcinomas and metastases to the
pelvis received neoadjuvant chemotherapy in accordance with the
standard regime for the particular primary carcinomas. Patient
17 also received neoadjuvant radiotherapy, whereas patient 22
required 6 cycles of adjuvant chemotherapy. The only other
diagnosis requiring neoadjuvant therapy was spindle cell carci-
noma, in which 4 cycles of chemotherapy were administered in
addition to radiotherapy.
There were 15 patients (62.5%) with a largest tumor diameter
of <10 cm, 6 patients (25%) with a tumor diameter between 10
and 20 cm, and 3 patients (12.5%) with ≥20 cm. Seven patients
presented with invasion of the neurovascular bundle by the
tumor. Two patients had both neural and vascular invasion, out
of whom 1 presented with invasion of the obturator nerve and
vessels, whereas the other had invasion of the sciatic nerve and
terminal branches of the external iliac artery. The most com-
monly involved nerve was the sciatic nerve (3 patients), followed
by the femoral, obturator, and sacral plexus in 1 patient each. The
only other patient with vascular involvement had invasion of
superior and inferior gluteal vessels along with obturator artery.
In each case, the involved nerve was dissected and the involved
vessel was divided and ligated. Negative margins were conﬁrmed
on frozen sections. For the minimum tumor-free margin, the
mean was calculated to be 0.8 ± 1.2 cm, whereas 4 patients still
had 1 positive resection margin. The mean intraoperative blood
loss was 1900 ± 1600mL, and subsequently, the mean intrao-
perative pack cell volume transfusion requirement was
1200 ± 1000mL, with a further requirement of 800 ± 700mL
during hospital stay. In addition, the mean transfusion require-
ment for fresh frozen plasma and platelets during hospital stay
was 400 ± 800mL and 100 ± 200mL, respectively.
Complications
Overall complications associated with hemipelvectomy are
summarized in Figure 1. In 2 cases, there was an injury to the
femoral nerve, whereas in 1 case, the sciatic nerve was partially
cut accidentally and each of these nerves were repaired. One
patient had injury to the urinary bladder and 1 patient suffered
injury to the prostatic urethra due to close proximity with the
tumor. Both injuries were managed with the help of a urologist.
Immediate postoperative bleeding was noted in 2 patients from
the internal iliac artery and required angioembolization. Two of
the early wound infections were managed with antibiotics,
whereas 2 required surgical debridement. Late wound infections
were noted at a mean of 30 ± 16 days after surgery, out of which 2
patients had superﬁcial infections and were managed by anti-
biotics, whereas the rest required a mean of 1.6 (range, 1–3)
surgical debridements. Two patients with ﬂap necrosis presented
at the 21st and 34th postoperative days with necrotic rectus
abdominus ﬂaps and both were managed with a second vastus
lateralis ﬂap.
Oncologic outcome
Local recurrence was noted in 3 patients (12.5%) at a mean of
4 months (range, 1–6mo) postoperatively. No signiﬁcant corre-
lation was found between recurrence and diagnosis, tumor size,
or the administration of adjuvant therapy as shown in Table 2.
The mean percentage response to neoadjuvant therapy was found
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to be signiﬁcantly lower in patients with recurrence compared
with those without recurrence (P=0.04). Both cases of Ewing
sarcoma recurrence were managed with chemotherapy, but the
patients died 2 and 10 months after recurrence, whereas the
patient with giant cell tumor was lost to follow-up.
A total of 7 patients (29.2%) developed metastatic disease at a
mean of 18.8 ± 20 months after surgery and the most common
site for metastasis was the lungs in 5 patients (71.4%). Other sites
involved were the brain (1 patient) and the knee joint (1 patient).
Table 3 shows different factors associated with the development
of metastases of primary pelvic tumors, none of which were
found to be signiﬁcant.
Survival and functional outcome
The mean survival was calculated to be 28 months. The Kaplan-
Meier analysis in Graph 1 shows a 2-year survival rate of 50%.
There was no signiﬁcant association between survival and other
Table 1
Characteristics of the study population.
Patient No. Age (y) Sex Diagnosis Stage Largest Tumor Diameter (cm) Type of Hemipelvectomy
1 17 Male Spindle cell carcinoma IIB 10–20 I
2 25 Female Chondrosarcoma IIB 10–20 I/II
3 16 Female Ewing sarcoma IIB < 10 I/II
4 16 Male Ewing sarcoma IIB < 10 II/III
5 14 Female Ewing sarcoma IIB < 10 I/II/III
6 32 Male Chondrosarcoma IIB 10–20 III
7 30 Female Giant cell tumor III 10–20 I
8 21 Male Osteosarcoma IIB < 10 II
9 8 Male Ewing sarcoma IIB ≥ 20 I/II/IV
10 47 Male Giant cell tumor III ≥ 20 I/II
11 16 Male Osteosarcoma IIB 10–20 I/II/III
12 13 Male Ewing sarcoma IIB < 10 III
13 5 Male Ewing sarcoma IIB < 10 I/II
14 15 Male Ewing sarcoma IIB < 10 I
15 14 Male Ewing sarcoma IIB < 10 I
16 22 Female Ewing sarcoma III < 10 I/II
17 55 Female Lung carcinoma IV < 10 I/II/III
18 12 Female Ewing sarcoma IIB < 10 I
19 14 Female Ewing sarcoma IIB < 10 I/IV
20 40 Male Osteosarcoma IIB ≥ 20 I/II/III
21 33 Male Rectal carcinoma IV < 10 I/IV
22 42 Female Endometrial carcinoma IV < 10 II/III
23 17 Male Ewing sarcoma IIB 10–20 I/II/IV
24 45 Female Hydatid disease III < 10 II/III
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Figure 1. Frequency of different complications noted.
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characteristics including the presence of metastases (P= 0.25),
local recurrence (P=0.35), tumor size (P=0.21), and require-
ment of ﬂap reconstruction (P=0.77). The meanMSTS score for
the surviving patients was 19.3 ± 5.2. Five of the 14 patients were
walking without support, whereas 1 patient was bedridden. The
rest were using either canes or crutches for ambulation. It was
found that patients who needed ﬂap coverage had a signiﬁcantly
lower mean MSTS as compared with those patients who did not
(P= 0.03).
Discussion
Internal hemipelvectomy is performed for all pelvic tumors
including primary bone and soft tissue sarcomas and secondary
metastatic tumors, with the intention of either local tumor control
or palliative care and pain control. The most common malignant
pelvic tumor is reported to be chondrosarcoma, followed by
Ewing sarcoma and osteosarcoma [1,5,13]. In comparison, most of
our patient’s had Ewing sarcoma and only 8% of the patients had
chondrosarcoma. An epidemiological study conducted in
Pakistan in 2010 showed a similar prevalence of different bone
sarcomas as shown in the international literature, but it did not
address site-speciﬁc prevalence, and therefore the possibility of a
different prevalence pattern for pelvic tumors in Pakistan com-
pared with the western world cannot be excluded [14]. The mean
follow-up period was comparable to that of other studies, but
it was noted that around 21% of the patients were lost to
follow-up [7,15]. In our setting, most of the patients belong to
lower socioeconomic classes and also come from distant places,
and hence ﬁnancial constraints and inadequate transportation
could be the possible causes of loss to follow-up.
The most common complication noted in our study was
wound infections, which also corresponds to previously available
literature [1,2,15]. In terms of intraoperative complications, inju-
ries to the urinary tract have also been reported previously and
are attributed to the complex pelvic anatomy and close proximity
of all internal viscera [9]. We also reported 3 cases of iatrogenic
neurovascular injury, which were managed immediately without
any subsequent complications. It is important to note that in all 3
cases, the tumor size was > 10 cm, which indicates that maneu-
vering around themajor structures without damage and complete
tumor excision becomes more difﬁcult with an increased tumor
size. The 2 cases of dural tear and cerebrospinal ﬂuid leakage
were managed immediately with dural repair, followed by pla-
cement of lumbar drain. Donati et al[16] in their study for the
treatment of pelvic osteosarcoma also reported a case of dural
tear and a case of persistent cerebrospinal ﬂuid leakage out of 14
internal hemipelvectomy patients.
There were 3 cases of local recurrence, 2 of Ewing sarcoma,
and 1 case of giant cell tumor. Similar recurrence rates have also
Table 2
Characteristics with reference to the development of local
recurrence (n=24).
Local Recurrence [n (%)]
Characteristics Yes No P
Diagnosis 0.65
Ewing sarcoma 2 (16.7) 10 (83.3)
Osteosarcoma 0 3 (100)
Giant cell tumor 1 (50.0) 1 (50.0)
Spindle cell carcinoma 0 1 (100)
Chondrosarcoma 0 2 (100)
Hydatid disease 0 1 (100)
Metastatic disease 0 3 (100)
Tumor size (cm) 0.358
< 10 2 (13.3) 13 (86.7)
10–20 0 6 (100)
≥ 20 1 (33.3) 2 (66.7)
Adjuvant therapy 0.19
Yes 0 8 (100)
No 3 (18.8) 13 (81.2)
Table 3
Characteristics with reference to the development of metastasis in
cases of primary pelvic tumors (n=21).
Metastases [n (%)]
Characteristics Yes No P
Diagnosis 0.76
Ewing sarcoma 5 (41.7) 7 (58.3)
Osteosarcoma 1 (33.3) 2 (66.7)
Giant cell tumor 1 (50.0) 1 (50.0)
Spindle cell carcinoma 0 1 (100)
Chondrosarcoma 0 2 (100)
Hydatid disease 0 1 (100)
Tumor size (cm) 0.33
< 10 4 (33.3) 8 (66.7)
10–20 1 (16.7) 5 (83.3)
≥ 20 2 (66.7) 1 (33.3)
Chemoradiotherapy* 1.00
Yes 5 (33.3) 10 (66.7)
No 2 (33.3) 4 (66.7)
*Adjuvant or neoadjuvant therapy.
Graph 1. Kaplan-Meier analysis for survival.
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been reported previously [2,15,17]. It is however interesting to note
that all 3 patients had high-grade aggressive lesions, and recur-
rence occurred despite clear resection margins in each case. Even
though there was no signiﬁcant association between recurrence
and receiving adjuvant therapy, none of the 3 patients had
received adjuvant chemoradiation. This might suggest that
patients with high-grade lesions should receive adjuvant therapy
irrespective of resectionmargins. Previously, Pant et al[18] in 2000
also reported the recurrence of a high-grade pleomorphic osteo-
sarcoma after clear margins, which further supports the sugges-
tion. Recurrence of Ewing sarcoma could also be attributed to the
signiﬁcantly reduced response to neoadjuvant therapy in both
cases. There is still a lack of literature on evaluating the impor-
tance of response to neoadjuvant treatment in preventing recur-
rence of pelvic tumors after hemipelvectomy.
The overall distant metastasis rate after hemipelvectomy has
been shown to range from 13.3% to 28% in international lit-
erature, in comparison with 29.2% reported in our study [8,17]. It
is important to note that all of the tumors in this study were high
grade, stage IIB and above for malignant lesions, and stage III for
benign lesions, which could be a possible reason for the higher
rate of metastasis. In addition, this also shows that all patients
had delayed presentation, which can again be attributed to the
transportation and ﬁnancial constraints, and therefore it is
important to improve the overall health care infrastructure for
effective intervention and referrals in developing countries such
as Pakistan.However, themeanMSTS score is still comparable to
that of previous studies, and a signiﬁcantly lower score in patients
requiring ﬂap coverage highlights the increased morbidity asso-
ciated with reconstruction [8,15].
One of the major limitations of this study is its retrospective
design, and therefore the dependence on patient record ﬁles for
follow-up data. Another limitation is the small sample size and a
short mean follow-up period. More such studies are required
from the developing world with long-term follow-ups to identify
the complications and long-term outcomes of hemipelvectomy.
An important ﬁnding was the reduced response rate of neoadju-
vant therapy in both cases of Ewing sarcoma recurrence. This
might suggest a need to revisit the chemoradiation therapy pro-
tocol, but more data frommultiple centers are required to reach a
conclusion.
Conclusions
Hemipelvectomy is the mainstay of treatment for pelvic tumors.
The type of hemipelvectomy is dependent on various factors
including the extent of disease and patient preference. The similar
outcomes and prevalence of complications shown in this study
compared with international literature suggests that hemi-
pelvectomy is a viable option in developing countries also. Some
important ﬁndings pointed out in the study were the different
tumor prevalence pattern and reduced response to neoadjuvant
therapy in Ewing sarcoma leading to recurrence. However, as
there is a considerable lack of literature from developing and
Asian countries, more such studies are warranted to validate
these ﬁndings and to identify the challenges and morbidities
associated with hemipelvectomy in these regions.
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